These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 12176853)

  • 1. Development of vaccines against common colds.
    Olszewska W; Zambon M; Openshaw PJ
    Br Med Bull; 2002; 62():99-111. PubMed ID: 12176853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
    Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccines for the prevention of respiratory viral infections: problems and current status.
    Olszewska W; Helson R; Openshaw PJ
    Expert Opin Investig Drugs; 2004 Jun; 13(6):681-9. PubMed ID: 15174954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination against acute respiratory virus infections and measles in man.
    Osterhaus AD; de Vries P
    Immunobiology; 1992 Feb; 184(2-3):180-92. PubMed ID: 1587542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Infections with respiratory viruses].
    Popow-Kraupp T
    Ther Umsch; 1994 Aug; 51(8):563-8. PubMed ID: 7940414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current progress on development of respiratory syncytial virus vaccine.
    Chang J
    BMB Rep; 2011 Apr; 44(4):232-7. PubMed ID: 21524347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in Vaccines to Prevent Viral Respiratory Illnesses in Children.
    Anderson AJ; Snelling TL; Moore HC; Blyth CC
    Paediatr Drugs; 2017 Dec; 19(6):523-531. PubMed ID: 28808938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with respiratory syncytial virus vaccines.
    Piedra PA
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S94-9. PubMed ID: 12671459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.
    Liu X; Liang B; Ngwuta J; Liu X; Surman S; Lingemann M; Kwong PD; Graham BS; Collins PL; Munir S
    J Virol; 2017 Nov; 91(22):. PubMed ID: 28835504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy?
    Munoz FM
    Curr Opin Infect Dis; 2015 Jun; 28(3):221-4. PubMed ID: 25918956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys.
    Tang RS; MacPhail M; Schickli JH; Kaur J; Robinson CL; Lawlor HA; Guzzetta JM; Spaete RR; Haller AA
    J Virol; 2004 Oct; 78(20):11198-207. PubMed ID: 15452239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization against respiratory virus infections.
    Hobson D
    Mod Trends Immunol; 1967; 2():53-85. PubMed ID: 4298139
    [No Abstract]   [Full Text] [Related]  

  • 13. Respiratory viral infections in the elderly.
    Treanor J; Falsey A
    Antiviral Res; 1999 Dec; 44(2):79-102. PubMed ID: 10669259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
    Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
    J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines.
    Durbin AP; Karron RA
    Clin Infect Dis; 2003 Dec; 37(12):1668-77. PubMed ID: 14689350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.
    Mackow N; Amaro-Carambot E; Liang B; Surman S; Lingemann M; Yang L; Collins PL; Munir S
    J Virol; 2015 Oct; 89(20):10319-32. PubMed ID: 26223633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of recombinant Sendai virus vaccines for prevention of human parainfluenza and respiratory syncytial virus infections.
    Hurwitz JL
    Pediatr Infect Dis J; 2008 Oct; 27(10 Suppl):S126-8. PubMed ID: 18820573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoparticle vaccines against respiratory viruses.
    Adair BM
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2009; 1(4):405-14. PubMed ID: 20049806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
    Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
    Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
    Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.